Search clinical trials for: CORT118335

Total 10 results

Corcept Therapeutics

Completed

First-in-human Study in Healthy Subjects

Healthy

United Kingdom
Corcept Therapeutics

Recruiting

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Completed

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

Healthy

United Kingdom
Corcept Therapeutics

Recruiting

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Nonalcoholic Steatohepatitis (NASH) | Metabolic Dysfunction-associated Steatohepatitis (MASH)

United States, Puerto Rico
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
The Scripps Research Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo

Alcohol Use Disorder

United States
Corcept Therapeutics

Completed

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

Healthy

United Kingdom
Corcept Therapeutics

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Corcept Therapeutics

Completed

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Antipsychotic-induced Weight Gain

United Kingdom
Corcept Therapeutics

Completed

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Non-alcoholic Steatohepatitis (NASH) | Antipsychotic Induced Weight Gain

United States

3

Subscribe